MétaCan
Menu
Back to cohort
Record W2886769372 · doi:10.1093/brain/awy204

Optimal use of cholinergic drugs in Alzheimer’s disease

2018· letter· en· W2886769372 on OpenAlexaff
Serge Gauthier, Nathan Herrmann, Pedro Rosa‐Neto

Bibliographic record

VenueBrain · 2018
Typeletter
Languageen
FieldMedicine
TopicCholinesterase and Neurodegenerative Diseases
Canadian institutionsSunnybrook Health Science CentreHealth Sciences CentreMcGill UniversityDouglas Mental Health University Institute
Fundersnot available
KeywordsCholinergicAlzheimer's diseaseNeuroscienceDiseaseMedicineTacrinePsychologyPharmacologyAcetylcholinesteraseInternal medicineBiology

Abstract

fetched live from OpenAlex

Sir We read with great interest the review article by Hampel et al. (2018) on the cholinergic system in Alzheimer’s disease. Sadly, despite the strength of the evidence towards a beneficial effect of cholinesterase inhibitors in Alzheimer’s disease, the government of France withdrew reimbursement for these medications. While we ultimately hope for a precision medicine approach to treatment as suggested by Hampel et al., there is thus still an immediate need to better define the efficacy of symptomatic drugs in Alzheimer’s disease. In fact our group demonstrated the feasibility to quantify presynaptic cholinergic depletion in vivo (Aghourian et al., 2017). We propose an approach used in the treatment of major depression, where ‘treatment-resistant depression’ leads to change in treatment, such as a medication switch within a class or between class, and augmentation using various pharmacological and non-pharmacological means (McIntyre et al., 2014). An operational definition of ‘cholinesterase inhibitors non-responsive dementia’ could be agreed upon, and instead of indefinite prescription of cholinesterase inhibitors if well tolerated, as is currently done in most countries, a more structured approach to assessment of benefit would lead to cholinesterase inhibitor cessation or treatment modification based on the most prominent symptoms at the current stage of Alzheimer’s disease for individual patients. Along these lines, we are encouraged that evidence-based recommendations for deprescribing cholinesterase inhibitors are already appearing (Reeve et al., 2018). We think that this more structured approach to therapy in Alzheimer’s disease will encourage clinicians to use cholinesterase inhibitors when appropriate, and reassure third party payers that these drugs are used optimally. This will be even more important for new generations of drugs acting on various components of Alzheimer’s disease pathophysiology. Data sharing is not applicable to this article as no new data were created or analysed in this study. The authors report no competing interests.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.001
metaresearch head score (Gemma)0.014
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.022
Threshold uncertainty score0.019

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0010.014
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.001
Bibliometrics0.0010.000
Science and technology studies0.0020.001
Scholarly communication0.0020.002
Open science0.0010.001
Research integrity0.0220.015
Insufficient payload (model declined to judge)0.0040.003

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.066
GPT teacher head0.320
Teacher spread0.254 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2018
Admission routes1
Has abstractno

Explore more

Same venueBrainSame topicCholinesterase and Neurodegenerative DiseasesFrench-language works237,207